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Abstract
Morphine and structurally related derivatives are highly effective analgesics, and the mainstay in the medical management
of moderate to severe pain. Pharmacological actions of opioid analgesics are primarily mediated through agonism at the m
opioid peptide (MOP) receptor, a G protein-coupled receptor. Position 17 in morphine has been one of the most
manipulated sites on the scaffold and intensive research has focused on replacements of the 17-methyl group with other
substituents. Structural variations at the N-17 of the morphinan skeleton led to a diversity of molecules appraised as
valuable and potential therapeutics and important research probes. Discovery of therapeutically useful morphine-like drugs
has also targeted the C-6 hydroxyl group, with oxymorphone as one of the clinically relevant opioid analgesics, where a
carbonyl instead of a hydroxyl group is present at position 6. Herein, we describe the effect of N-substituent variation in
morphine and oxymorphone on in vitro and in vivo biological properties and the emerging structure-activity relationships.
We show that the presence of a N-phenethyl group in position 17 is highly favorable in terms of improved affinity and
selectivity at the MOP receptor, potent agonism and antinociceptive efficacy. The N-phenethyl derivatives of morphine and
oxymorphone were very potent in stimulating G protein coupling and intracellular calcium release through the MOP
receptor. In vivo, they were highly effective against acute thermal nociception in mice with marked increased
antinociceptive potency compared to the lead molecules. It was also demonstrated that a carbonyl group at position 6 is
preferable to a hydroxyl function in these N-phenethyl derivatives, enhancing MOP receptor affinity and agonist potency
in vitro and in vivo. These results expand the understanding of the impact of different moieties at the morphinan nitrogen
on ligand-receptor interaction, molecular mode of action and signaling, and may be instrumental to the development of
new opioid therapeutics.
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Introduction
The naturally occurring morphine (Figure 1), the active
component of opium, has been used as an analgesic for centuries
[1]. Today, effective pain control is still one of the most important
therapeutic priorities [2]. Morphine and other structurally related
derivatives as well as opioids with distinct structures such as
fentanyl have proven to be of the utmost importance as effective
analgesics for the treatment of moderate to severe pain. The
pharmacological actions of clinically used opioid analgesics are
primarily mediated through activation of the m opioid peptide
(MOP) receptor [3], highly expressed in the central and peripheral
nervous system and various peripheral tissues. The MOP receptor
together with the other members of the opioid receptor class, i.e. d
opioid peptide (DOP) and k opioid peptide (KOP) receptors,
belong to the family of G protein-coupled receptors (GPCRs), and
their crystal structures are now available [4–6]. While extremely
efficacious as pain relievers, opioid analgesics produce an array of
side effects that can limit their clinical usefulness, including
constipation, nausea, vomiting, and respiratory depression. Long-
term treatment with opioids is also associated with development of
tolerance to their analgesic effects, physical dependence and
addiction [7].
Since the structure elucidation of morphine ninety years ago, its
skeleton and its conversion to new analogues was intensively
investigated. Consequently, the morphinan skeleton has been the
basis of successful drug development, and several opioid drugs are
available for patient use or are employed as research probes to
examine opioid mechanisms at cellular and molecular levels [3,8–
13]. Extensive work in the field led to innovative molecules with
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new substitution patterns and more favorable pharmacological
features, powerful analgesia and less undesirable effects. Estab-
lished and generally accepted structure-activity relationship (SAR)
models have assigned a significant role to the N-substituent in
position 17 on the morphinan skeleton in defining the pharma-
cological behavior. Nalorphine, the N-allyl substituted analogue of
morphine, was one of the first compounds to be recognized as an
opioid antagonist, reversing the analgesic and respiratory depres-
sant actions of morphine [13,14]. Further studies described that
nalorphine alone can induce an antinociceptive effect, which was
almost comparable to that of morphine [15,16], thus defining
nalorphine as a partial agonist. Earlier reports on large series of
differently N-substituted derivatives of morphine provided exciting
outcomes. Exchanging the methyl group at the nitrogen of
morphine by other alkyl groups reduces or abolishes analgesic
activity [17]. N-Phenacyl-, N-phenoxyethyl-, and N-benzylnor-
morphine have less than one-tenth of the analgesic potency of
morphine [17]. In contrast, it was described that N-phenethyl
substitution resulted in a 6- to 10-fold higher analgesic potency
compared to morphine in rodents, while N-cyclohexylethylnor-
morphine was only one-third as effective [17]. Another targeted
site on the morphine skeleton is the C-14 position, where
introduction of a hydroxyl group induces an analgesic action of
moderate strength [18]. Numerous highly potent morphine-like
compounds are known, one of them being oxymorphone, a MOP
agonist (Figure 1). Oxymorphone is used not only clinically [19],
but also as a valuable scaffold for the development of new ligands
interacting with the MOP receptor [9,11,20]. A representative
example of the complex role played by the morphinan nitrogen in
determining the pharmacological properties includes N-substituted
derivatives of oxymorphone, ranging from potent agonism i.e. N-
methyl, N-benzyl and N-phenethyl, to partial agonism i.e. N-
dimethylallyl (nalmexone) and N-cyclobutylmethyl (nalbuphone),
to pure and potent antagonism i.e. N-allyl (naloxone) and N-
cyclopropylmethyl (naltrexone). Substitution of the methyl with a
phenylethyl group at the nitrogen in oxymorphone produces a 12-
fold increase in analgesic potency [21]. Naloxone and naltrexone,
the N-allyl- and N-cyclopropylmethyl analogues of oxymorphone,
respectively, are two opioid antagonists clinically used for the
treatment of opioid induced respiratory depression and overdose,
with naltrexone being also used for the management of opioid and
alcohol dependence [22,23]. In both morphine and oxymorphone
series, it has been reported that the 14-hydroxy group can
influence the morphine-like pharmacological profile for varying N-
substituents [24,25]. In the class of agonists, the C14-hydroxyl
appears to slightly reduce intrinsic in vitro potency, while increasing
in vivo potency. In partial agonists, the 14-hydroxyl group
considerably contributes in decreasing efficacy.
The present study was undertaken to characterize and to
compare the effect of N-substituent variation in morphine and
oxymorphone on in vitro (binding and functional activity) and
in vivo (nociception) pharmacological properties. SAR studies were
performed on a series comprising of four derivatives of morphine
(1–4) and two derivatives of oxymorphone (5 and 6) (Figure 1).
Although the synthesis of compounds 1 [26,27] and 3 [18] has
been reported about fifty years ago, and derivative 4 was prepared
twenty years ago [28], there is only spare data on their biological
activities, with binding affinities and selectivities at MOP, DOP
and KOP receptors not yet reported. Herein, we also describe the
synthesis and biological characterization of a new N-substituted
derivative of morphine, N-phenylpropylnormorphine (2). In the
oxymorphone series, the N-phenethyl substituted derivative 6 was
already prepared in the 1960s [29] and known as a potent opioid
analgesic [21], while N-benzylnoroxymorphone (5) was synthe-
sized and in vitro binding and in vivo behavioral studies were first
reported by May et al. [30]. To our knowledge, there are no in vitro
functional activity data at opioid receptors available on any of the
investigated morphine and oxymorphone derivatives. We have
evaluated the ability of these compounds to stimulate G protein
coupling (guanosine 59-O-(3-[35S]thio)triphosphate, [35S]GTPcS,
functional assay) in membranes of cells expressing the human
recombinant opioid receptors. Moreover, in cells co-expressing
opioid receptors and chimeric G proteins that force the receptor to
signal through the calcium pathway, these opioid ligands were
examined for their capability to promote calcium mobilization.
Furthermore, in vivo efficacy in mice against acute thermal
nociception (hot-plate and tail-flick tests) was examined and
compared to antinociceptive potencies of the lead molecules,
morphine and oxymorphone. These investigations provide valu-
able insights on SAR in the morphinan class of opioids, by
broadening our current understanding of the impact of different
moieties at the morphinan nitrogen on ligand-receptor interaction,
signaling and the link between analgesic efficacy and the molecular
mode of action.
Figure 1. Structures of morphine, oxymorphone and N-substituted morphinans 1–6. Ph, phenyl.
doi:10.1371/journal.pone.0099231.g001
Opioid Activities of N-phenethylmorphinans
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Materials and Methods
Ethics Statement
All animal studies were conducted in accordance with ethical
guidelines and animal welfare standards according to Austrian
regulations for animal research, and were approved by the
Committee of Animal Care of the Austrian Federal Ministry of
Science and Research. Every effort was made to minimize both
the animal suffering and the number of animals used.
Compounds and Reagents
Opioid radioligands, [3H][D-Ala2,Me-Phe4,Gly-ol5]enkephalin
([3H]DAMGO), [3H]5a,7a,8b-(2)N-methyl-N-[7-(1-pyrrolidinyl)-
1-oxaspiro(4,5)dec-8-yl]benzeneacetamide ([3H]U69,593) and
[35S]GTPcS were purchased from PerkinElmer (Boston, USA).
[3H][Ile5,6]deltorphin II was obtained from the Institute of
Isotopes Co. Ltd. (Budapest, Hungary). DAMGO, [D-Pen2,D-
Pen5]enkephalin (DPDPE), naloxone, tris(hydroxymethyl)amino-
methane (Tris), 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic
acid (HEPES), unlabeled GTPcS, guanosine diphosphate (GDP)
were obtained from Sigma-Aldrich Chemicals (St. Louis, MO,
USA). All cell culture media and supplements were from Sigma-
Aldrich Chemicals (St. Louis, MO, USA) and Invitrogen (Paisley,
UK). Morphine was obtained from Gatt-Koller GmbH (In-
nsbruck, Austria). All other chemicals were obtained from
standard commercial sources.
The synthesis of N-phenethylnormorphine (1) was performed
from normorphine by alkylation with 2-phenylethyl bromide
according to Clark et al. [26] using N,N-dimethylformamide
(DMF) instead of ethanol as solvent, which provided higher yields.
Similarly, N-phenylpropylnormorphine (2) was synthesized from
normorphine using 3-phenylpropyl bromide as alkylating agent.
Sodium borohydride reduction of 14-hydroxymorphinone in
ethanol yielded 14-hydroxymorphine (3) as previously described
[18]. N-Phenethyl-14-hydroxynormorphine (4) was prepared in
several steps from N-phenethylnorthebaine as earlier described
[28]. N-Benzylnoroxymorphone (5) [31] and N-phenethylnorox-
ymorphone (6) [21] were synthesized by a new route via
noroxymorphone ethylene ketal. For further details see Chemistry
S1.
In vitro Assays
Radioligand binding assays. Membranes were prepared
from Sprague-Dawley rat or guinea pig brains as previously
described [32]. All binding experiments were performed in
50 mM Tris-HCl buffer (pH 7.4) in a final volume of 1 ml
containing 300–500 mg protein [32]. Rat brain membranes were
incubated either with [3H]DAMGO (1 nM, 45 min, 35uC) or
[3H][Ile5,6]deltorphin II (0.5 nM, 45 min, 35uC). Guinea pig
brain membranes were incubated with [3H]U69,593 (1 nM,
30 min, 30uC). Nonspecific binding was determined in the
presence of 10 mM naloxone. Reactions were terminated by rapid
filtration using a Brandel Cell Harvester (Brandel Inc., Gaithers-
burg, MD) and Whatman GF/B glass fiber filters pre-soaked in
0.1% polyethylenimine for 1 h at 4uC for [3H]U69,593, or type
GF/C for [3H]DAMGO and [3H][Ile5,6]deltorphin II. Filters
were washed three times with 5 ml of ice-cold 50 mM Tris-HCl
buffer (pH 7.4) and bound radioactivity was measured by liquid
scintillation counting. All experiments were performed in duplicate
and repeated at least three times. Protein concentration was
determined by the Bradford method using bovine serum albumin
as the standard [33].
[35S]GTPcS functional assays. Chinese hamster ovary
(CHO) cells expressing recombinant human MOP, DOP or
KOP receptors (CHOhMOP, CHOhDOP and CHOhKOP cell lines)
were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) and Ham F-12 medium supplemented with fetal bovine
serum (FBS, 10%), penicillin/streptomycin (0.1%), L-glutamine
(2 mM) and geneticin (400 mg/ml) [34]. Cell cultures were
maintained at 37uC in 5% CO2 humidified air. Membranes were
prepared in buffer A (20 mM HEPES, 10 mM MgCl2 and
100 mM NaCl, pH 7.4) as described [35]. Cell membranes (5 mg)
were incubated with 0.05 nM [35S]GTPcS, 10 mM GDP and test
compounds for 60 min at 25uC, in a total volume of 1 ml.
Nonspecific binding was determined using 10 mM GTPcS, and
the basal binding was determined in the absence of test ligand.
Samples were filtered over Whatman GF/B glass fiber filters and
counted as described for binding assays. All experiments were
performed in triplicate and repeated at least three times.
Calcium mobilization assays. CHOhMOP and CHOhKOP
stably expressing the C-terminally modified Gaqi5 protein, and
CHOhDOP stably expressing the C-terminally modified GaqG66Di5
protein were grown in DMEM/Ham F-12 medium supplemented
with FBS (10%), penicillin (100 IU/ml), streptomycin (100 mg/
ml), L-glutamine (2 mM), geneticin (200 mg/ml) and hygromycin
B (100 mg/ml). Cell cultures kept at 37uC in 5% CO2 in
humidified air were used in the calcium mobilization assays
performed as previously described [36]. Cells were seeded at a
Table 1. Opioid receptor binding affinities and selectivities at MOP, DOP and KOP receptors.
Ki (nM) Selectivity ratios
MOP DOP KOP DOP/MOP KOP/MOP
Morphine 6.5560.74 217619 11369 33 17
Oxymorphone 0.9760.05 80.565.5 61.661.2 83 51
1 0.9360.14 37.065.5 107618 40 115
2 79.561.1 8696171 565624 11 7
3 16.461.1 1,0816271 789677 66 48
4 4.6060.01 163617 513666 35 112
5 359631 1,078635 75.068.0 3 0.2
6 0.5460.03 12.860.2 84.267.2 24 156
Binding assays were performed with membranes from rat brain (MOP and DOP receptors) and guinea pig brain (KOP receptors).
Values represent the mean 6 SEM of at least three experiments each performed in duplicate.
doi:10.1371/journal.pone.0099231.t001
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density of 50,000 cells per well into 96-well black, clear-bottom
plates. After 24 h, the cells were loaded with medium supple-
mented with 2.5 mM probenecid, 3 mM of the calcium sensitive
fluorescent dye Fluo-4 AM and 0.01% pluronic acid, for 30 min at
37uC. The loading solution was replaced by Hank’s Balanced Salt
Solution (HBSS) supplemented with 20 mM HEPES, 2.5 mM
probenecid and 500 mM Brilliant Black, for 10 min at 37uC. After
placing both plates (cell culture and compound plate) into the
FlexStation II (Molecular Device, Union City, CA), fluorescence
changes were recorded. All experiments were performed in
duplicate and repeated at least three times.
In vivo Testing
Animals. Sprague-Dawley rat and guinea pig brains used in
in vitro assays were obtained from the Institut fu¨r Labortierkunde
und Laborgenetik, Medizinische Universita¨t Wien (Himberg,
Austria). Male CD1 mice (25–30 g) were used in in vivo studies.
Mice were housed in groups of five and were kept in a
temperature-regulated environment under a controlled 12 h
light/dark cycle with free access to food and water at all times
except during testing.
Drug administration. Vehicle or solutions of test com-
pounds prepared in sterile physiological saline (0.9%) were
administered subcutaneously (s.c.) to mice in a volume of 10 ml
per 1 g body weight. At least three doses were tested, and 5–6
animals per dose were used. The dose ranges for the investigated
opioids were: morphine (1.25–5 mg/kg), oxymorphone (0.2–
1 mg/kg), and compounds 1 (0.05–0.5 mg/kg), 4 (0.5–5 mg/kg),
and 6 (0.1–0.5 mg/kg).
Nociceptive assessments. The hot-plate test was performed
as described [37]. Each mouse was placed on a UB 35100 hot/
cold plate (Ugo Basile s.r.l., Varese, Italy) kept at 55uC, and the
occurrence of a nociceptive response (licking or shaking a paw,
jumping) was observed. To confine the mice to a certain
observation area, a colourless plastic cylinder of 20 cm diameter
was placed on the hot plate. In order to avoid possible tissue
injury, a cut-off time of 12 s was used. The tail-flick test was
performed using an UB 37360 Ugo Basile analgesiometer (Ugo
Basile s.r.l., Varese, Italy) as previously described [37]. The
reaction time required by the mouse to remove its tail due to the
radiant heat was measured and defined as the tail-flick latency. A
cut-off time of 10 s was used in order to minimize tissue damage.
Hot-plate and tail-flick latencies were measured before (basal
latency, BL) and 30, 60 and 120 min after drug or vehicle s.c.
administration (test latency, TL). For establishing the dose-
response effect, the antinociceptive response was expressed as
percent of Maximum Possible Effect (%MPE) = [(TL – BL)/(cut-
off time – BL)]6100 for each dose tested.
Data Analysis
Binding and functional data were analyzed with the GraphPad
Prism software (GraphPad Software Inc., San Diego, CA).
Concentration-response curves were constructed and inhibition
constant (Ki, nM), agonist potency (EC50, nM) and efficacy (Emax,
as percentage of maximum stimulation with respect to the
standard opioid agonists, DAMGO (MOP), DPDPE (DOP) and
U69,593 (KOP)) were calculated using nonlinear curve fitting
analysis. Data are represented as the mean 6 SEM. For in vivo
assays, the effective dose ED50 and 95% confidence limits (95%
CL) were calculated using the method of Litchfield and Wilcoxon
[38].
Results and Discussion
Opioid receptor binding affinities and selectivities of the four
derivatives of morphine (1–4) and two derivatives of oxymorphone
(5 and 6) were determined by in vitro competition binding assays
using membranes from rat brain (MOP and DOP opioid
receptors) or guinea pig brain (KOP opioid receptors) [32].
Receptor type-specific radioligands were used i.e. [3H]DAMGO
(MOP), [3H][Ile5,6]deltorphin II (DOP) and [3H]U69,593 (KOP).
Binding affinities expressed as Ki values and selectivity ratios are
listed in Table 1. For comparison purposes, opioid binding
affinities of morphine and oxymorphone are included in Table 1.
In the series of morphine derivatives, the N-phenethyl substi-
tuted 1 displayed the highest MOP receptor affinity
(Ki = 0.93 nM), being 7-fold greater than the affinity of morphine.
The other N-phenethyl substituted analogue 4 with a 14-hydroxyl
group also showed high MOP receptor affinity in the low
nanomolar range similar to that of morphine (Table 1). A lower
binding affinity to the MOP receptor was exhibited by the new N-
Figure 2. In vitro agonist activities at the MOP receptor of morphine, oxymorphone and N-methylmorphinans 1, 4 and 6.
Concentration-response curves in (A) [35S]GTPcS functional assay with membranes from CHO expressing human MOP receptor and (B) calcium
mobilization experiments performed with CHO cells co-expressing the human MOP receptor and the Gaqi5 protein. Activity is calculated as
percentage of maximal stimulation produced by DAMGO. Data are shown as the mean 6 SEM (n$3).
doi:10.1371/journal.pone.0099231.g002
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phenylpropylnormorphine (2) and 14-hydroxymorphine (3). Gen-
erally, all morphine derivatives 1–4 had one to two orders of
magnitude decreased affinities at DOP and KOP receptors.
Concerning MOP selectivity, with the exception of the new N-
phenylpropyl substituted 2, the other three derivatives had
comparable selectivity vs. DOP, and increased selectivity vs.
KOP receptors. The presence of a hydroxyl group at position 14
in N-phenethyl-14-hydroxynormorphine (4) resulted in about 5-
fold lower affinity at the MOP receptor paralleled by decreased
interaction with DOP and KOP receptors as compared to its 14-
unsubtituted counterpart 1, although leaving MOP selectivity
unchanged. Furthermore, replacement of the N-phenethyl substit-
uent in 1 with a N-phenylpropyl group (2) largely reduces both
binding affinity and selectivity at the MOP receptor (Table 1).
Exchanging the 17-methyl group in 14-hydroxymorphine (3) with
a phenethyl moiety (4) increases binding affinity at the MOP
receptor by about 4-fold, with a slight decrease in DOP/MOP and
an increase in KOP/MOP selectivity ratios.
Compared to the parent molecule oxymorphone, the N-
phenethyl substituted analogue 6 exhibited almost 2-fold higher
affinity at the MOP receptor and better MOP vs. KOP receptor
selectivity. On the contrary, the other derivative 5 showed much
reduced interaction with MOP receptors, and very low MOP
selectivity (Table 1), indicating that a benzyl group at N-17 is not
favorable for both MOP affinity and selectivity. Our present
observations on the low binding profile at the MOP receptor of the
N-benzyl substituted derivative of oxymorphone (5) agree with
previously reported binding data (Ki values of 138 nM for MOP,
529 nM for DOP, and 134 nM for KOP) [30]. N-Phenethylnor-
oxymorphone (6) displayed about 9-fold increased MOP receptor
affinity and similar DOP/MOP and KOP/MOP selectivity ratios
compared to its analogue in the morphine series, N-phenethyl-14-
hydroxynormorphine (4). Similar observations are made when
comparing oxymorphone with its 14-hydroxy analogue 3 (Table 1).
Among the investigated N-phenethyl substituted compounds,
the two morphine derivatives 1 and 4 and the oxymorphone
analogue 6, showing high binding affinity and selectivity at the
MOP receptor (Table 1), were selected for further in vitro and
in vivo studies. The other derivatives (2, 3 and 5), due to their
reduced interaction with the MOP receptor together with much
lower binding affinities to this receptor than the parent molecules
morphine or oxymorphone (Table 1), where not considered for
additional investigations. First, compounds 1, 4 and 6 were
examined for agonist potencies and efficacies in vitro. In this study
it was of utmost relevance to assess initially MOP receptor-
mediated G protein activation by these opioid agonists. The used
functional approaches assessed stimulation of [35S]GTPcS binding
and intracellular calcium mobilization. The effect of the investi-
gated compounds was compared to that of the parent molecules
morphine and oxymorphone, and to the profile of the standard
opioid agonists, DAMGO (MOP), DPDPE (DOP) and U69,593
(KOP). Potencies as EC50 values and efficacies as maximum
response (Emax) to the reference opioid agonists are presented in
Table 2. Opioid receptor-mediated G protein signaling was
evaluated using a [35S]GTPcS binding assay in membranes from
CHO cells stably expressing either the human MOP, DOP or
KOP receptors [35]. In CHOhMOP cell membranes, all three
compounds 1, 4 and 6 produced concentration-dependent
increase in [35S]GTPcS binding (Figure 2A). Oxymorphone
derivative 6 was the most potent MOP agonist with an EC50
value of 2.63 nM, roughly equivalent to that of oxymorphone,
while also showing similar efficacies. This N-phenethyl substituted
6 also proved to be more potent than DAMGO (EC50 = 19.3 nM)
in stimulating G protein signaling. High agonist potency was also
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depicted by the morphine derivative 1, being about 3-fold more
potent as MOP agonist than morphine, and 2-fold than DAMGO.
In contrast, the N-phenethyl-14-hydroxynormorphine (4) exhibit-
ed the lowest potency having an EC50 value similar to morphine
(Table 2). The rank order of agonist potencies to promote MOP
receptor mediated-G protein coupling correlates well with binding
affinities at the MOP receptor observed in the radioligand binding
studies (Table 1).
By comparing the agonist potency at the hMOP receptor
expressing CHO cells, potencies of derivatives 1, 4 and 6,
morphine and oxymorphone to stimulate [35S]GTPcS binding
were decreased considerably in hDOP (EC50 = 3.0 nM for
DPDPE) and hKOP receptors (EC50 = 42.7 nM for U69,593)
expressing cells (Table 2). While in CHOhDOR cell membranes,
they showed high efficacies, much reduced to no stimulation was
measured at the KOP receptor. Due to very low binding affinity at
the KOP receptor (Ki = 513 nM), we did not investigate the
activity at the KOP receptor of compound 4 in the [35S]GTPcS
binding.
In this study, we have also examined the potency and efficacy of
derivatives 1, 4 and 6 to evoke changes in intracellular calcium
concentration using a whole cell fluorescence-based assay [36]. In
CHOhMOP cells stably expressing the Gaqi5 chimeric protein, all
compounds produced a concentration-dependent stimulation of
calcium release (Figure 2B). It is notable that the rank order of
EC50 values correlated well with the EC50 values obtained in
[35S]GTPcS binding assays (Table 2), with N-phenethylnorox-
ymorphone (6) showing the highest potency. Compared to
DAMGO (EC50 = 42.7 nM), compound 6 was about 2-fold more
potent. Among the two morphine derivatives, N-phenethylnor-
morphine (1) was about 3-fold more potent than morphine and
equipotent to DAMGO, and about 3-fold more active than its 14-
hydroxy analogue 4 in evoking calcium mobilization (Table 2). In
CHOhDOP cells expressing the GaqG66Di5 chimeric protein, and in
CHOhKOP cells expressing the Gaqi5 chimeric protein, the
investigated derivatives stimulated calcium release with consider-
ably lower potencies or were even found inactive, which is in line
with the findings from [35S]GTPcS functional assays (Table 2).
The findings from our in vitro studies including binding affinity
and potency at the MOP receptor together with earlier reports on
the analgesic effects of compounds 1 [17] and 6 [21] and
preliminary experiments were used to establish the appropriate
dose range for in vivo investigations. Antinociceptive properties of
morphine derivatives 1 and 4, and oxymorphone analogue 6 were
assessed in mice after s.c. administration using two nociceptive
tests, hot-plate and tail-flick [37]. All three MOP agonists
produced time- and dose-dependent effects in both nociceptive
assays (Figures 3 and 4) with compounds 1 and 6 being the most
effective against acute thermal nociception. The peak antinocicep-
tion occurred generally 30 min after drug s.c. administration
(Figure 3). Antinociceptive potencies expressed as ED50 values
with 95% confidence limits are listed in Table 3, and were
compared with those of the reference opioids drugs, morphine and
oxymorphone. In agreement with the earlier observations of
Winter et al. [17], morphine derivative 1 was also shown in our
study to be a more potent antinociceptive than morphine. In the
hot-plate and tail-flick tests, it was 22- and 28-fold, respectively,
more effective than morphine. First data on the antinociceptive
effect of N-phenethyl-14-hydroxynormorphine (4) are described
herein, revealing this MOP agonist as a potent antinociceptive
agent with a 2- to 3-fold increased potency than morphine.
Compound 6, the N-phenethyl analogue of oxymorphone, was
found to be highly active with about 2-fold higher potency than
oxymorphone, and comparable potency to 1. It was up to 8-fold
more potent than its 6-hydroxy counterpart 4 in inducing an
antinociceptive response, indicating a 6-keto substitution to be
preferable toward improved analgesic properties. Besides analge-
sia, MOP agonists are well-known to induce other behavioral
changes. While in this study, generally, no major alterations in
locomotor activity and no sedative effects were observed at any of
the tested doses of compounds 1, 4 and 6, representing about 3- to
4-fold the analgesic ED50 dose, further investigations will be
needed to establish the therapeutic index of these compounds.
Conclusions
Position 17 in morphine has been one of the most manipulated
sites on the scaffold and intensive research has focused on
replacements of the 17-methyl group with other substituents.
Structural variations at the N-17 of the morphinan skeleton have
Figure 3. Time-course of antinociceptive effects produced by morphine, oxymorphone and N-methylmorphinans 1, 4 and 6. The
effect of morphine (1.25–5 mg/kg), oxymorphone (0.2–1 mg/kg), and compounds 1 (0.05–0.5 mg/kg), 4 (0.5–5 mg/kg), and 6 (0.1–0.5 mg/kg) in the
hot-plate test (A, left panel) and in the tail-flick test (B, right panel). Hot-plate and tail-flick latencies (in seconds) were determined in mice before
(0 min) and after s.c. drug administration (30, 60 and 120 min). Data are shown as the mean 6 SEM (n=5–6 mice per group).
doi:10.1371/journal.pone.0099231.g003
Figure 4. Dose-dependent antinociceptive effects produced by morphine, oxymorphone and N-methylmorphinans 1, 4 and 6. (A)
Hot-plate test. (B) Tail-flick test. Hot-plate and tail-flick latencies (as %MPE) are shown at 30 min (peak of action) after s.c. drug administration to mice.
Data are shown as the mean 6 SEM (n=5–6 mice per group).
doi:10.1371/journal.pone.0099231.g004
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resulted in a diversity of compounds appraised as valuable and
therapeutic agents and important research tools [3,9,11,12].
Furthermore, discovery of therapeutically useful morphine-like
drugs has also targeted the C-6 hydroxyl group, with oxymor-
phone as one example of the clinically relevant opioid analgesics,
where a carbonyl instead of a hydroxyl group is present at position
6 [9,39]. Taken together, in the present study we highlight on the
significant outcomes of N-substituent variation in morphine and
oxymorphone on in vitro and in vivo biological properties and the
emerging SAR. The presented data clearly reflect that a N-
phenethyl moiety in position 17 is highly favorable regarding
enhanced affinity and selectivity at the MOP receptor, potent
agonism and antinociceptive action. The increased lipophilicity of
the N-phenethyl derivatives compared to the parent compounds
may also contribute to the increased potency. Besides, it was also
demonstrated that a carbonyl group at position 6 is preferable to a
hydroxyl function in the N-phenethyl substituted molecules,
augmenting MOP receptor affinity and agonist potency in vitro
and in vivo. Though morphine derivatives, N-phenethylnormor-
phine (1) and N-phenethyl-14-hydroxynormorphine (4), and the
oxymorphone analogue N-phenethylnoroxymorphone (6) have
been developed many years ago, this is the first report on their
opioid receptor binding and signaling, and antinociceptive
efficacy. This report clarifies the activity of these molecules at
the opioid receptors for the first time, serving as a systematic study
of understanding their mode of action and the link between
agonist-induced G protein signaling events leading to the high
analgesic efficacy. Moreover, these results reveal that targeting
position 17 is a viable approach toward improving the pharma-
cological properties, and may be instrumental to the development
of new opioids for therapeutic use in the clinic. Considering the
interesting functional profile of these MOP agonists and their high
efficacy as antinociceptive agents, it is of interest to investigate
other intracellular signaling pathways (i.e. interactions with
regulatory proteins such as b-arrestins) and their side-effect profile
in future studies.
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